TAS-120-301(FOENIX-CCA3)
| ClinicalTrials.gov Identifier |
| NCT04093362 |
| Institution Name |
| Mayo Clinic |
| Institution City |
| Phoenix |
| Institution State |
| Arizona |
| Institution ZIP Code |
| 85004 |
| Institution Country |
| United States |
| Additional Institutions |
| Please refer to the Clinical Trials. gov listing and contact the Taiho Help Line at clinicaltrialinfo@ |
| Principal Investigator |
| Mitesh Borad, MD |
| Additional Principal Investigators |
| Please refer to the Clinical Trials. gov listing and contact the Taiho Help Line at clinicaltrialinfo@taihooncology.com for a site list |
| Additional Study Coordinators |
| Please refer to the Clinical Trials. gov listing and contact the Taiho Help Line at clinicaltrialinfo@ |
| Study Overview |
| FGFR2(fibroblast growth factor receptor 2) gene rearrangements, have been identified as an early driver of oncogenic events in approximately 15% of CCA patients. Futibatinib (TAS-120),an oral, highly selective, irreversible tyrosine kinase inhibitor (TKI) that inhibits FGFR1-4 isoforms, and have shown evidence of efficacy on CCA. |
| Enrollment Information |
| 216 |
| Study Start Date |
| 20200807 |
| Study End Date |
| 20230930 |
| Study Purpose |
|
| Financial Assistance Available |
| Yes |